Ketamine is an FDA-approved anesthetic, amnestic and analgesic that has been in wide use around the world in operating rooms, emergency rooms and trauma fields for over half a century and is on the World Health Organization’s list of essential medications. Current research suggests that ketamine infusions poses a myriad of groundbreaking but unconventional attributes that hold a lot of promise in the future of CPS and MDD.

Over the past 15 years, ketamine infusions have been relentlessly studied as an alternative treatment for refractory depression, chronic pain syndromes, post-traumatic stress disorder and many other conditions and they illuminated great success.

Although Ketamine is FDA approved, its use in these conditions is “off-label” and it is currently not covered by insurance. It is estimated that almost 25% of all prescription medications sold in the United States are prescribed off-label. While thousands of patients are having success with this treatment there is no guarantee of relief of pain, depressive symptoms or length of remission should it be achieved.